Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

NCT00298467 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00298467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00298467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Withdrawn
Start date
February 28, 2006
Completion date
Not reported
Enrollment
45 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, large-cell